Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes (Review)
- Authors:
- Marta Magdalena Fudalej
- Anna Maria Badowska‑Kozakiewicz
-
Affiliations: Department of Cancer Prevention, Medical University of Warsaw, 02‑091 Warsaw, Poland - Published online on: March 28, 2021 https://doi.org/10.3892/ol.2021.12678
- Article Number: 417
This article is mentioned in:
Abstract
 |
|
Ahmed M: Recent advances in the management of gastrointestinal stromal tumor. World J Clin Cases. 8:3142–3155. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto H and Oda Y: Gastrointestinal stromal tumor: Recent advances in pathology and genetics. Pathol Int. 65:9–18. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hirota S: Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry. Transl Gastroenterol Hepatol. 3:272018. View Article : Google Scholar : PubMed/NCBI | |
|
Khoshnood A: Gastrointestinal stromal tumor-A review of clinical studies. J Oncol Pharm Pract. 25:1473–1485. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kupcinskas J: Small molecules in rare tumors: Emerging role of MicroRNAs in GIST. Int J Mol Sci. 19:3972018. View Article : Google Scholar | |
|
Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH and Hinika GS: Gastrointestinal stromal tumors: A comprehensive review. J Gastrointest Oncol. 10:144–154. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H and Liu Q: Prognostic indicators for gastrointestinal stromal tumors: A review. Transl Oncol. 13:1008122020. View Article : Google Scholar : PubMed/NCBI | |
|
von Mehren M and Joensuu H: Gastrointestinal stromal tumors. J Clin Oncol. 36:136–143. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, et al: Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine (Baltimore). 96:e82402017. View Article : Google Scholar : PubMed/NCBI | |
|
Li HL, Wang LH, Hu YL, Feng Y, Li XH, Liu YF, Li P, Mao QS and Xue WJ: Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors. World J Gastroenterol. 26:4656–4668. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida T, Blay JY, Hirota S, Kitagawa Y and Kang YK: The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 19:3–14. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schaefer IM, Marino-Enriquez A and Fletcher JA: What is new in gastrointestinal stromal tumor? Adv Anat Pathol. 24:259–267. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Den Hollander D, Van der Graaf WTA, Desar IME and Le Cesne A: Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST). Acta Oncol. 58:1648–1654. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu KH, Tsai HW, Lin PW, Hsu YS, Lu PJ and Shan YS: Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J Surg Oncol. 12:1892014. View Article : Google Scholar : PubMed/NCBI | |
|
Wei SC, Xu L, Li WH, Li Y, Guo SF, Sun XR and Li WW: Risk stratification in GIST: Shape quantification with CT is a predictive factor. Eur Radiol. 30:1856–1865. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miettinen M and Lasota J: Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 130:1466–1478. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Di Vita M, Zanghi A, Cavallaro A, Cardì F, Uhlig M, Ursi P, Lo Menzo E, Panebianco V and Cappellani A: Gastric GIST and prognostic models. Which is the best to predict survival after surgery? Ann Ital Chir. 90:31–40. 2019.PubMed/NCBI | |
|
Wong NA: Gastrointestinal stromal tumours--an update for histopathologists. Histopathology. 59:807–821. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Imamura M, Yamamoto H, Nakamura N, Oda Y, Yao T, Kakeji Y, Baba H, Maehara Y and Tsuneyoshi M: Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol. 20:529–537. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rey S, Schito L, Wouters BG, Eliasof S and Kerbel RS: Targeting Hypoxia-Inducible factors for antiangiogenic cancer therapy. Trends Cancer. 3:529–541. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Teleanu RI, Chircov C, Grumezescu AM and Teleanu DM: Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med. 9:842019. View Article : Google Scholar | |
|
Liu N, Huang J, Sun S, Zhou Z, Zhang J, Gao F and Sun Q: Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors. Int J Clin Exp Med. 8:6495–6501. 2015.PubMed/NCBI | |
|
Tasdemir A, Soyuer I, Unal D and Artis T: Prognostic value of NF-κB, CD9, and VEGF in gastrointestinal stromal tumors. Contemp Oncol (Pozn). 17:493–498. 2013.PubMed/NCBI | |
|
Basilio-de-Oliveira RP and Pannain VL: Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol. 21:6924–6930. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kigure W, Fujii T, Sutoh T, Morita H, Katoh T, Yajima RN, Yamaguchi S, Tsutsumi S, Asao T and Kuwano H: The association of VEGF-C expression with tumor lymphatic vessel density and lymph node metastasis in patients with gastric cancer and gastrointestinal stromal tumor. Hepatogastroenterology. 60:277–280. 2013.PubMed/NCBI | |
|
Yang Z, Wang F, Liu S and Guan W: Comparative clinical features and short-term outcomes of gastric and small intestinal gastrointestinal stromal tumours: A retrospective study. Sci Rep. 9:100332019. View Article : Google Scholar : PubMed/NCBI | |
|
Gromova P, Rubin BP, Thys A, Cullus P, Erneux C and Vanderwinden JM: ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours. J Cell Mol Med. 16:306–317. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
de Oliveira AT, Reis RM, Afonso J, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS and Longatto-Filho A: Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours. Histol Histopathol. 26:1499–1507. 2011.PubMed/NCBI | |
|
Hui Q, Jin Z, Li X, Liu C and Wang X: FGF family: From drug development to clinical application. Int J Mol Sci. 19:18752018. View Article : Google Scholar | |
|
Boichuk S, Galembikova A, Mikheeva E, Bikinieva F, Aukhadieva A, Dunaev P, Khalikov D, Petrov S, Kurtasanov R, Valeeva E, et al: Inhibition of FGF2-Mediated Signaling in GIST-promising approach for overcoming resistance to imatinib. Cancers (Basel). 12:16742020. View Article : Google Scholar | |
|
Sergei B, Pavel D, Aigul G, Firyuza B, Ilmira N, Ilshat M, Aida A, Refat K, Natalia A, Elena S and Vera G: Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors. Int J Mol Sci. 21:3522020. View Article : Google Scholar | |
|
Li F, Huynh H, Li X, Ruddy DA, Wang Y, Ong R, Chow P, Qiu S, Tam A, Rakiec DP, et al: FGFR-Mediated Reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 5:438–451. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Cong Z, Qiang Y, Xiong L, Tang L, Zhang Y, Wu H, Yi J, Jing H, Li D and Shen Y: Clinical significance of CCBE1 expression in lung cancer. Mol Med Rep. 17:2107–2112. 2018.PubMed/NCBI | |
|
Tian GA, Zhu CC, Zhang XX, Zhu L, Yang XM, Jiang SH, Li RK, Tu L, Wang Y, Zhuang C, et al: CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib. Sci Rep. 6:310712016. View Article : Google Scholar : PubMed/NCBI | |
|
Mesci A, Huang X, Taeb S, Jahangiri S, Kim Y, Fokas E, Bruce J, Leong HS and Liu SK: Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. Br J Cancer. 116:1350–1357. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CJ, Zhang ZZ, Xu J, Wang M, Zhao WY, Tu L, Zhuang C, Liu Q, Shen YY, Cao H and Zhang ZG: SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis. World J Gastroenterol. 21:8398–8407. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjölund K and Nilsson B: Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: Evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 14:853–863. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ran L, Chen Y, Sher J, Wong EWP, Murphy D, Zhang JQ, Li D, Deniz K, Sirota I, Cao Z, et al: FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor. Cancer Discov. 8:234–251. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG and Zheng D: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467:849–853. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, et al: Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 5:304–315. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, et al: Platelet-Derived Growth Factor Receptor-α Regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by Stabilizing ETV1. Gastroenterology. 149:420–432.e16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sakamaki K, Funasaka K, Miyahara R, Furukawa K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Hirooka Y, Fujishiro M and Goto H: Low ETV1 mRNA expression is associated with recurrence in gastrointestinal stromal tumors. Sci Rep. 10:147672020. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Han W, Pelkey KA, Duan J, Mao X, Wang YX, Craig MT, Dong L, Petralia RS, McBain CJ and Lu W: Molecular Dissection of Neuroligin 2 and Slitrk3 reveals an essential framework for GABAergic Synapse Development. Neuron. 96:808–826.e8. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Agaimy A: Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: More questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 3:461–471. 2010.PubMed/NCBI | |
|
Hotzel J, Melling N, Muller J, Polonski A, Wolters-Eisfeld G, Izbicki JR, Karstens KF and Tachezy M: Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol. 145:2285–2292. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Karstens KF, Bellon E, Polonski A, Wolters-Eisfeld G, Melling N, Reeh M, Izbicki JR and Tachezy M: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power. Oncotarget. 11:1131–1140. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thys A, Vandenberghe P, Hague P, Klein OD, Erneux C and Vanderwinden JM: Hyperplasia of interstitial cells of cajal in sprouty homolog 4 deficient mice. PLoS One. 10:e01248612015. View Article : Google Scholar : PubMed/NCBI | |
|
Vandenberghe P, Hague P, Hockman SC, Manganiello VC, Demetter P, Erneux C and Vanderwinden JM: Phosphodiesterase 3A: A new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST). Oncotarget. 8:41026–41043. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dragomir M, Mafra ACP, Dias SMG, Vasilescu C and Calin GA: Using microRNA networks to understand cancer. Int J Mol Sci. 19:18712018. View Article : Google Scholar | |
|
Isosaka M, Niinuma T, Nojima M, Kai M, Yamamoto E, Maruyama R, Nobuoka T, Nishida T, Kanda T, Taguchi T, et al: A screen for epigenetically silenced microRNA genes in gastrointestinal stromal tumors. PLoS One. 10:e01337542015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Li J, Kuang D, Wang X, Zhu Y, Xu S, Chen Y, Cheng H, Zhao Q, Duan Y and Wang G: MiR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT. Cell Commun Signal. 16:162018. View Article : Google Scholar : PubMed/NCBI | |
|
Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, Zhou J and Yuan F: MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. Tumour Biol. 35:4209–4217. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yun S, Kim WK, Kwon Y, Jang M, Bauer S and Kim H: Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. Int J Cancer. 142:2080–2093. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, Zhou J and Yuan F: MicroRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Clin Exp Med. 15:137–144. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, et al: Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res. 72:1126–1136. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Niinuma T, Kai M, Kitajima H, Yamamoto E, Harada T, Maruyama R, Nobuoka T, Nishida T, Kanda T, Hasegawa T, et al: Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors. Oncol Lett. 14:5703–5710. 2017.PubMed/NCBI | |
|
Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Awasthi R, Rathbone MJ, Hansbro PM, Bebawy M and Dua K: Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Deliv Transl Res. 8:97–110. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mansoori B, Mohammadi A, Shirjang S and Baradaran B: MicroRNAs in the diagnosis and treatment of cancer. Immunol Invest. 46:880–897. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Catela Ivkovic T, Voss G, Cornella H and Ceder Y: MicroRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett. 407:113–122. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, et al: Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73:3499–3510. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Y, Garcia-Buitrago MT, Trent JC and Rosenberg AE: The immune system and gastrointestinal stromal tumor: A wealth of opportunities. Curr Opin Oncol. 27:338–342. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tan Y, Trent JC, Wilky BA, Kerr DA and Rosenberg AE: Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther. 24:130–133. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, et al: Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 17:1094–1100. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Seifert AM, Zeng S, Zhang JQ, Kim TS, Cohen NA, Beckman MJ, Medina BD, Maltbaek JH, Loo JK, Crawley MH, et al: PD-1/PD-L1 Blockade Enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 23:454–465. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J and Birnbaum D: PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 4:e10027292015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao R, Song Y, Wang Y, Huang Y, Li Z, Cui Y, Yi M, Xia L, Zhuang W, Wu X and Zhou Y: PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Prolif. 52:e125712019. View Article : Google Scholar : PubMed/NCBI | |
|
Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, et al: Use of PD-1 Targeting, Macrophage Infiltration, and IDO pathway activation in sarcomas: A Phase 2 clinical trial. JAMA Oncol. 4:93–97. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HC, Li TY, Chao YJ, Hou YC, Hsueh YS, Hsu KH and Shan YS: KIT Exon 11 Codons 557–558 deletion mutation promotes liver metastasis through the CXCL12/CXCR4 axis in gastrointestinal stromal tumors. Clin Cancer Res. 22:3477–3487. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RJP, Provasi E, Sarnicola ML, Panzeri I, et al: Transcriptional landscape of human tissue lymphocytes unveils uniqueness of Tumor-Infiltrating T regulatory cells. Immunity. 45:1135–1147. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka A and Sakaguchi S: Regulatory T cells in cancer immunotherapy. Cell Res. 27:109–118. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Soler D, Chapman TR, Poisson LR, Wang L, Cote-Sierra J, Ryan M, McDonald A, Badola S, Fedyk E, Coyle AJ, et al: CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol. 177:6940–6951. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yesilkanal AE and Rosner MR: Targeting Raf kinase inhibitory protein regulation and function. Cancers (Basel). 10:3062018. View Article : Google Scholar | |
|
Wang Y, Chen JJ, Wang XF and Wang Q: Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors. World J Gastroenterol. 24:2508–2517. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yesilkanal AE and Rosner MR: Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: Regulation of signaling networks in cancer. Crit Rev Oncog. 19:447–454. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Valadao M, Braggio D, Santos AF, Pimenta-Inada HK, Linhares E, Gonçalves R, Romano S, Vilhena B, Small I, Cubero D, et al: Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. J Surg Res. 178:288–293. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y and Weinberg RA: Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities. Front Med. 12:361–373. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, Mi Z and Kuo PC: Osteopontin-A master regulator of Epithelial-Mesenchymal transition. J Clin Med. 5:392016. View Article : Google Scholar | |
|
Shevde LA and Samant RS: Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 37:131–141. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS and Lu PJ: Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol. 17:3043–3052. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Senbanjo LT and Chellaiah MA: CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 5:182017. View Article : Google Scholar : PubMed/NCBI | |
|
Hu JC, Wang Q, Jiang LX, Cai L, Zhai HY, Yao ZW, Zhang ML and Feng Y: Effect of long non-coding RNA AOC4P on gastrointestinal stromal tumor cells. Onco Targets Ther. 11:6259–6269. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Lu C, Huang X, Cui J, Li J, Gao Y, Liang W, Liu Y, Sun Y, Liu H, et al: Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer. Therap Adv Gastroenterol. 12:17562848198276972019. View Article : Google Scholar : PubMed/NCBI | |
|
Hao Y, Baker D and Ten Dijke P: TGF-beta-Mediated Epithelial-Mesenchymal transition and cancer metastasis. Int J Mol Sci. 20:27672019. View Article : Google Scholar | |
|
Kovecsi A, Gurzu S, Szentirmay Z, Kovacs Z, Bara TJ and Jung I: Paradoxical expression pattern of the epithelial mesenchymal transition-related biomarkers CD44, SLUG, N-cadherin and VSIG1/Glycoprotein A34 in gastrointestinal stromal tumors. World J Gastrointest Oncol. 9:436–443. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pulkka OP, Nilsson B, Sarlomo-Rikala M, Reichardt P, Eriksson M, Hall KS, Wardelmann E, Vehtari A, Joensuu H and Sihto H: SLUG transcription factor: A pro-survival and prognostic factor in gastrointestinal stromal tumour. Br J Cancer. 116:1195–1202. 2017. View Article : Google Scholar : PubMed/NCBI |
